Idiopathic pulmonary fibrosis (IPF) remains a truly idiopathic fibrotic disease, with a modest
genetic predilection and candidate triggers but no overall explanation for the development of …

Background Approximately one‐third of individuals with interstitial lung disease (ILD) have
associated connective tissue disease (CTD). The connective tissue disorders most …

Objectives Assess the efficacy and safety of tocilizumab in patients with systemic sclerosis
(SSc) in a phase II study. Methods Patients with SSc were treated for 48 weeks in an open …

Objectives SSc is characterized by fibrotic changes in the skin and lung, and the mainstay of
treatment has been CYC. B cell involvement suggests that rituximab (RTX) may also be of …

Objectives To identify the predictive clinical characteristics and establish a prediction model
for the progression of mild interstitial lung disease (ILD) in patients with systemic sclerosis …

A proportion of patients with interstitial lung diseases (ILDs) are at risk of developing a
progressive-fibrosing phenotype, which is associated with a deterioration in lung function …

Rationale: FVC percent predicted (FVC%) is the primary outcome measure in clinical trials of
systemic sclerosis interstitial lung disease. For interpretation of change in the FVC% over …

Objective Systemic sclerosis (SSc) is a progressive fibrotic disease that affects the skin and
internal organs. Despite evidence implicating increased interleukin-17 (IL-17) activity in SSc …

Rationale: The Scleroderma Lung Study II (SLS II) demonstrated significant improvements in
pulmonary function and dyspnea at 24 months compared with baseline when patients with …

ABSTRACT Background: Interstitial lung diseases (ILDs) are among the most serious
complications associated with systemic rheumatic diseases, and lead to significant morbidity …